Calcineurin Inhibitors: 40 Years Later, Can’t Live Without …

Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine. The early impressive results of cyclosporine in kidney transplant recipients led to its subsequent use in other organ transplant recipients and for treatment of a variety of autoimmune diseases as well. In this review, we examine the discovery of CNIs, their mechanism of action, preclinical and clinical studies with CNIs, and the usage of CNIs in nontransplant recipients. We review the mechanisms of renal toxicity associated with CNIs and the recent efforts to avoid or reduce usage of these drugs. Although minimization strategies are possible, safe, and of potential long-term benefit, complete avoidance of CNIs has proven to be more challenging than initially thought.

[1]  J. Azzi,et al.  Belatacept: a new era of immunosuppression? , 2012, Expert review of clinical immunology.

[2]  Y. De Launoit,et al.  In Vitro Effects of Cyclosporine A and Tacrolimus on Regulatory T-Cell Proliferation and Function , 2012, Transplantation.

[3]  L. Tang,et al.  Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A , 2012, Journal of transplantation.

[4]  A. Sharif,et al.  Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. , 2011, Journal of the American Society of Nephrology : JASN.

[5]  C. A. Utine Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections , 2011, Clinical ophthalmology.

[6]  Li Tang,et al.  Polylactide‐cyclosporin A nanoparticles for targeted immunosuppression , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  M. Stern,et al.  Clinical Review: Topical Ophthalmic Use of Cyclosporin A , 2010, Ocular immunology and inflammation.

[8]  P. Friend,et al.  Five-year safety and efficacy of belatacept in renal transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[9]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  L. Rostaing,et al.  A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  F. Conti,et al.  Inhibitory effects of cyclosporine on human regulatory T cells in vitro. , 2009, Transplantation proceedings.

[12]  P. Halloran,et al.  Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  F. Schena,et al.  Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial , 2009, Transplantation.

[14]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[15]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[16]  J. Papadimitriou,et al.  Early Withdrawal of Calcineurin Inhibitors and Rescue Immunosuppression with Sirolimus‐Based Therapy in Renal Transplant Recipients with Moderate to Severe Renal Dysfunction , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  J. Luño,et al.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. , 2007, Kidney international.

[18]  G. Knoll,et al.  Conversion From Calcineurin Inhibitors to Sirolimus for Chronic Renal Allograft Dysfunction: A Systematic Review of the Evidence , 2006, Transplantation.

[19]  H. Asanuma,et al.  Posterior reversible encephalopathy syndrome in children: its high prevalence and more extensive imaging findings. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  L. Haragsim,et al.  Nephrotoxicity as a complication of antiretroviral therapy. , 2006, Advances in chronic kidney disease.

[21]  B. Baird,et al.  Role of maintenance immunosuppressive regimen in kidney transplant outcome. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[22]  B. Griffith,et al.  A randomized trial of inhaled cyclosporine in lung-transplant recipients. , 2006, The New England journal of medicine.

[23]  V. Dharnidharka Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.

[24]  M. Zand Immunosuppression and Immune Monitoring After Renal Transplantation , 2005, Seminars in dialysis.

[25]  M. Schnitzler,et al.  Renal Graft Survival and Calcineurin Inhibitor , 2005, Transplantation.

[26]  K. Natarajan,et al.  Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.

[27]  V. Nickeleit,et al.  Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P‐glycoprotein , 2005, Pharmacotherapy.

[28]  D. Goldfarb,et al.  The natural history of chronic allograft nephropathy. , 2005, The Journal of urology.

[29]  M. Gubler,et al.  Improvement of Renal Function in Pediatric Heart Transplant Recipients Treated with Low-Dose Calcineurin Inhibitor and Mycophenolate Mofetil , 2005, Transplantation.

[30]  M. Sayegh,et al.  Transplantation 50 years later--progress, challenges, and promises. , 2004, The New England journal of medicine.

[31]  R. Balshaw,et al.  New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta‐Analysis , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  H. Meier‐Kriesche,et al.  Pharmacology of calcineurin antagonists. , 2004, Transplantation proceedings.

[33]  A. Meyrier Treatment of idiopathic nephrosis by immunophillin modulation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  S. Takahara,et al.  Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan1 , 2003, Transplantation.

[35]  J. Borel History of the discovery of cyclosporin and of its early pharmacological development. , 2002, Wiener klinische Wochenschrift.

[36]  F. Moreso,et al.  Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. , 2002, Kidney international.

[37]  A. Pletscher,et al.  The controversial early history of cyclosporin. , 2001, Swiss medical weekly.

[38]  L. Hebert,et al.  Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. , 2001, Kidney international.

[39]  M. Nicholson,et al.  Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia–reperfusion injury , 2000, The British journal of surgery.

[40]  L. Hebert,et al.  A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. , 1999, Kidney international.

[41]  G. Appel,et al.  Cyclosporine treatment of glomerular diseases. , 1999, Annual review of medicine.

[42]  F. Pociot,et al.  The natural history of an HLA haplotype and its recombinants , 1998, Immunogenetics.

[43]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[44]  E. Price,et al.  Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4 , 1996, Nature.

[45]  E. A. O'neill,et al.  T cell responses in calcineurin A alpha-deficient mice , 1996, The Journal of experimental medicine.

[46]  H. Stähelin The history of cyclosporin A (Sandimmune®) revisited: Another point of view , 1996, Experientia.

[47]  F. Schmid,et al.  Protein folding: Prolyl isomerases join the fold , 1995, Current Biology.

[48]  F. Follath,et al.  [Cyclosporin in autoimmune diseases]. , 1994, Schweizerische medizinische Wochenschrift.

[49]  S. Schreiber,et al.  Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location , 1993, Molecular and cellular biology.

[50]  A. Edefonti,et al.  A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome , 1993, Pediatric Nephrology.

[51]  T. Annesley,et al.  Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. , 1991, The New England journal of medicine.

[52]  H. Schäfers,et al.  [Unilateral lung transplantation--a new perspective in the treatment of pulmonary fibrosis]. , 1990, Pneumologie.

[53]  R. Lilford,et al.  BENEFITS OF IN-VITRO FERTILISATION , 1989, The Lancet.

[54]  W. Savage,et al.  GYNAECOLOGISTS' ATTITUDES TO ABORTION , 1989, The Lancet.

[55]  J. Voorhees,et al.  Cyclosporine in dermatology. , 1989, Journal of the American Academy of Dermatology.

[56]  C. Klee,et al.  Domain II of calmodulin is involved in activation of calcineurin , 1988, FEBS letters.

[57]  J. Harper,et al.  CYCLOSPORIN FOR PSORIASIS , 1984, The Lancet.

[58]  D. Cooley,et al.  Early results of cardiac transplantation at the Texas Heart Institute. , 1984, Thorax.

[59]  European Multicentre Study Group CYCLOSPORIN IN CADAVERIC RENAL TRANSPLANTATION: ONE-YEAR FOLLOW-UP OF A MULTICENTRE TRIAL , 1983, The Lancet.

[60]  G. Kolata Drug transforms transplant medicine. , 1983, Science.

[61]  G. Klintmalm,et al.  Liver transplantation with use of cyclosporin a and prednisone. , 1981, The New England journal of medicine.

[62]  D. Dunn,et al.  CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERS , 1979, The Lancet.

[63]  D. Dunn,et al.  CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS , 1978, The Lancet.

[64]  A. Barrett,et al.  CYCLOSPORIN A FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN MAN , 1978, The Lancet.

[65]  R. Calne,et al.  PROLONGED SURVIVAL OF PIG ORTHOTOPIC HEART GRAFTS TREATED WITH CYCLOSPORIN A , 1978, The Lancet.

[66]  A. Allison,et al.  EXTENSIVE PROLONGATION OF RABBIT KIDNEY ALLOGRAFT SURVIVAL AFTER SHORT-TERM CYCLOSPORIN-A TREATMENT , 1978, The Lancet.

[67]  R. Calne RENAL TRANSPLANTATION , 1977, The Lancet.

[68]  J. Borel,et al.  Biological effects of cyclosporin A: A new antilymphocytic agent , 1976, Agents and actions.

[69]  Hill Mm Living organisms in patent law. , 1970 .

[70]  Roger Williams,et al.  Methods and Devices: IMPROVED LIVER-BIOPSY NEEDLE , 1969 .

[71]  L. Haragsim,et al.  Calcineurin nephrotoxicity. , 2006, Advances in chronic kidney disease.

[72]  H. Rugstad,et al.  Cyclosporine and rheumatoid arthritis , 2005, Springer Seminars in Immunopathology.

[73]  H. Date,et al.  [Lung transplantation]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[74]  A. Fleischer,et al.  Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. , 2001, Journal of the American Academy of Dermatology.

[75]  R. Langley,et al.  Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. , 2001, Journal of the American Academy of Dermatology.

[76]  B. Borello [Histories of the history of women]. , 1999, Clio.

[77]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[78]  C. Bagnis,et al.  Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. , 1997, American journal of nephrology.

[79]  J. Pirsch,et al.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. , 1997, Transplantation.

[80]  S. Shenolikar,et al.  Protein serine/threonine phosphatases--new avenues for cell regulation. , 1994, Annual review of cell biology.

[81]  J. Szulmajster Protein folding , 1988, Bioscience reports.

[82]  A. Tejani Cyclosporine treatment in patients with primary glomerular diseases. , 1987, The International journal of pediatric nephrology.

[83]  O. Førre,et al.  An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. , 1987, Arthritis and rheumatism.

[84]  G. Opelz Multicenter impact of ciclosporin on cadaver kidney graft survival. , 1986, Progress in allergy.

[85]  Unilateral lung transplantation for pulmonary fibrosis. , 1986, The New England journal of medicine.

[86]  A randomized clinical trial of cyclosporine in cadaveric renal transplantation. , 1983, The New England journal of medicine.

[87]  M. Polley Renal transplantation. , 1967, Nursing times.